Richard D. Kim, MD

Richard Kim, MD, walks through options in the frontline setting for patients with advanced staged hepatocellular carcinoma and how newer treatments have impacted this patient population.

Considerations for ongoing clinical trials that may shape the future treatment landscape of unresectable hepatocellular carcinoma.

Richard Kim, MD, shares insight on positive results from IMbrave150, which tested the frontline combination of atezolizumab and bevacizumab in patients with unresectable HCC.

A brief synopsis on optimal sequencing strategies for patients who have been diagnosed with unresectable hepatocellular carcinoma.

A comprehensive overview of the frontline treatment landscape for patients with unresectable HCC, including those who present with contraindications to standard-of-care therapy.

Expert Richard Kim, MD, reflects on the nature of HCC, particularly the challenges inherent in diagnosis and management.